Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
View stock
VS
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
View stock

Stock highlights

Stock comparison highlights
Stock name
Armata PharmaceuticalsJohnson & Johnson
Last price
$3.84$254.54
Currency
USD
USD
$136M$610B
-29.32
-$5.27$8.63
1.350.23
0$5.28
02.12%
Sector
HealthHealth
Employees
61138,200
Ticker
$ARMP$JNJ
Primary listing
AMEXNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $ARMP or $JNJ on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.